CDK16

Cyclin-dependent kinase 16 · Q00536 · CDK16 on Sugi Atlas →

21,485 patent compounds predicted against CDK16, 18,350 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Riviciclib (SCHEMBL290347)	1.00	2/20
Riviciclib (SCHEMBL663219)	1.00	2/20
Riviciclib (SCHEMBL663220)	1.00	2/20
Riviciclib (SCHEMBL290572)	0.98	2/20
Riviciclib (SCHEMBL291157)	0.98	2/20
Riviciclib (SCHEMBL665748)	0.98	2/20
Riviciclib (SCHEMBL665749)	0.98	2/20
SCHEMBL291051	0.74	2/20
SCHEMBL291052	0.74	2/20
SCHEMBL291053	0.74	2/20
Hydrochloric Acid (SCHEMBL665647)	0.66	2/20
SCHEMBL666139	0.64	2/20
SCHEMBL291158	0.61	2/20
SCHEMBL823917	0.59	2/20
SCHEMBL699059	0.50	2/20
Quizartinib (SCHEMBL72923)	1.00	1/20
Bms-345541 (SCHEMBL118886)	1.00	1/20
Uprosertib (SCHEMBL168584)	1.00	1/20
Pictilisib (SCHEMBL190812)	1.00	1/20
Ribociclib (SCHEMBL302310)	1.00	1/20

Clinical trials — most relevant to CDK16 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)	PHASE3	COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients	PHASE3	RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
RP-6306 in Patients With Advanced Cancer	PHASE2	COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO	PHASE2	COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma	PHASE2	WITHDRAWN
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics	PHASE1	COMPLETED
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy	nan	COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
The SONImage Study	nan	ACTIVE_NOT_RECRUITING
Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor	nan	UNKNOWN
Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CDK16 binder may also engage these)

Protein	Name	Similarity
Q63686	—	1.000	Q63686 →
Q04735	—	0.999	Q04735 →
O35832	—	0.996	O35832 →
O35831	—	0.995	O35831 →
Q04899	—	0.994	Q04899 →
C0RW22	—	0.993	C0RW22 →
P51138	—	0.993	P51138 →
Q8VZD5	—	0.993	Q8VZD5 →
Q8K0D0	—	0.993	Q8K0D0 →
Q5RD01	—	0.992	Q5RD01 →
B0VXL7	—	0.992	B0VXL7 →
DCLK1	Serine/threonine-protein kinase DCLK1	0.992	landscape →
Q8I7M8	—	0.991	Q8I7M8 →
O35495	—	0.991	O35495 →
CDK17	Cyclin-dependent kinase 17	0.991	landscape →
CDK14	Cyclin-dependent kinase 14	0.991	landscape →
Q5VP69	—	0.990	Q5VP69 →
Q96287	—	0.990	Q96287 →
Q0TWJ7	—	0.990	Q0TWJ7 →
P43289	—	0.990	P43289 →
Q6DJM7	—	0.990	Q6DJM7 →
Q9C9U2	—	0.989	Q9C9U2 →
Q9JLM8	—	0.989	Q9JLM8 →
Q5SN53	—	0.989	Q5SN53 →
O23145	—	0.989	O23145 →
O08875	—	0.989	O08875 →
P43288	—	0.989	P43288 →
Q40518	—	0.989	Q40518 →
Q9LV37	—	0.989	Q9LV37 →
B6A7Q3	—	0.989	B6A7Q3 →